ConductScience.org, home

Comparison · NCT01228435-9fed87c6

ALK-inhibitor Naive vs ALK-inhibitor Pre-treated: Response Rate

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. ALK-inhibitor Naive vs ALK-inhibitor Pre-treated: Response Rate. Trial comparisons, record NCT01228435-9fed87c6. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01228435-9fed87c6

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.793wilson
Risk in group 2000.658wilson
Risk difference, group 1 minus group 20-0.6580.793newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treatfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1ALK-inhibitor NaivePatients in this arm has no prior exposure to ALK-inhibitor and were treated with IPI-504 at 225mg/m2 twice a week for 2 weeks followed by 10 days off with cycles repeating every 21 days.01OG000
Group 2ALK-inhibitor Pre-treatedPatients in this arm had received prior exposure to ALK-inhibitor and were treated with IPI-504 at 225mg/m2 twice a week for 2 weeks followed by 10 days off with cycles repeating every 21 days.02OG001

Outcome

Type
PRIMARY
Title
Response Rate
Description
The response rate was defined as the number of patients achieving a RECIST 1.0 defined response divided by the number of patients treated and was to be calculated separately for each arm. A response by RECIST criteria means that the pre-defined target lesions (sum of the longest diameters) had to decrease by 30% or more and this response needed to be confirmed on a second scan at least 4 weeks later.
Time frame
2 years
Population

Source ClinicalTrials.gov

Trial

Title
IPI-504 in NSCLC Patients With ALK Translocations
NCT number
NCT01228435
Phases
PHASE2
Conditions
Lung Cancer, Stage IIIb Lung Cancer, Stage IV Lung Cancer
Interventions
IPI-504
Lead sponsor
Massachusetts General Hospital
Results first posted
2013-10-23

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01228435-9fed87c6